Please use this identifier to cite or link to this item:
Title: Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer
Authors: El Hachem, Georges
Gombos, Andrea
Awada, Ahmad
Affiliations: Faculty of Medicine 
Keywords: CDK 4/6 inhibitors
Luminal breast cancer
Brain metastases
Hormone receptor positive
Issue Date: 2021
Publisher: Taylor & Francis Online
Part of: Expert Review of Anticancer Therapy
Volume: 21
Issue: 1
Start page: 81
End page: 92
The field of metastatic luminal breast cancer (hormone receptor positive, HER-2 negative) is dynamic and evolving, harboring some of the most significant therapeutic advances in medical oncology. Over the last decade, many pivotal trials showed excellent results with drastic improvements in survival as well as the quality of life of metastatic luminal breast cancer patients.
ISSN: 14737140
DOI: 10.1080/14737140.2020.1834385
Ezproxy URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Jun 15, 2024

Record view(s)

checked on Jun 21, 2024

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.